Fulcrum Therapeutics (FULC) Interest & Investment Income (2018 - 2026)
Fulcrum Therapeutics (FULC) reported Interest & Investment Income of $3.3 million for Q1 2026, up 19.91% year-over-year from $2.7 million in Q1 2025, and up 39.68% quarter-over-quarter from $2.4 million in Q4 2025.
Fulcrum Therapeutics (FULC) Interest & Investment Income (2018 - 2026) Analysis & Trends
Fulcrum Therapeutics (FULC) has 9 years of Interest & Investment Income data on file, last reported at $3.3 million in Q1 2026.
- Interest & Investment Income for Q1 2026 came in at $3.3 million, up 19.91% year-over-year; the trailing twelve-month figure through Mar 2026 was $10.4 million (down 12.71% YoY), and the FY2025 annual result was $9.9 million, down 18.76% from the prior year.
- Interest & Investment Income rose to $3.3 million in Q1 2026 per FULC's latest filing, from $2.4 million in the prior quarter.
- Over five years, Interest & Investment Income peaked at $3.5 million in Q2 2023 and troughed at $70000.0 in Q1 2022.
- A 5-year average of $2.4 million and a median of $2.9 million in 2024 frame the typical range for Interest & Investment Income.
- The sharpest annual moves came in 2023 and 2025: Interest & Investment Income soared 4415.71% in 2023, then tumbled 34.02% in 2025.
- A 5-year view of Interest & Investment Income shows it stood at $1.8 million in 2022, then jumped by 76.06% to $3.2 million in 2023, then fell by 11.59% to $2.9 million in 2024, then retreated by 17.55% to $2.4 million in 2025, then surged by 39.68% to $3.3 million in 2026.
- Business Quant data shows FULC's Interest & Investment Income at $3.3 million in Q1 2026, $2.4 million in Q4 2025, and $2.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | 597,319.59 |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 40.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | 305,000.00 |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | 103,341.00 |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 114.80 Mn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -14.79 Mn |
| 10 | Fulcrum Therapeutics | 267.90 Mn | 267.90 Mn | - | 3.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.30 Mn |
| Dec 31, 2025 | 2.36 Mn |
| Sep 30, 2025 | 2.26 Mn |
| Jun 30, 2025 | 2.52 Mn |
| Mar 31, 2025 | 2.75 Mn |
| Dec 31, 2024 | 2.86 Mn |
| Sep 30, 2024 | 3.43 Mn |
| Jun 30, 2024 | 2.92 Mn |
| Mar 31, 2024 | 2.96 Mn |
| Dec 31, 2023 | 3.24 Mn |
| Sep 30, 2023 | 3.42 Mn |
| Jun 30, 2023 | 3.51 Mn |
| Mar 31, 2023 | 3.16 Mn |
| Dec 31, 2022 | 1.84 Mn |
| Sep 30, 2022 | 617,000.00 |
| Jun 30, 2022 | 165,000.00 |
| Mar 31, 2022 | 70,000.00 |
| Dec 31, 2021 | 75,000.00 |
| Sep 30, 2021 | 54,000.00 |
| Jun 30, 2021 | 34,000.00 |